News

Black and white photo of a bearded man in very 70s apparel standing in front of a banner with "David Baltimore" and the mirror image text'

Remembering David Baltimore

MIT Koch Institute

With sadness, the Koch Institute marks the passing of Professor David Baltimore. A founding faculty member and formative influence behind the MIT Center for Cancer Research, he was not only a ground-breaking researcher but also a compelling and thoughtful voice for science. 

His discovery of reverse transcriptase changed the prevailing scientific dogma, earned him a 1975 Nobel Prize, and directly enables work in life sciences and biomedical laboratories everywhere. His decades-long advocacy work impacted national policy debates on topics such as recombinant DNA research, the AIDS epidemic, and genome editing.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Directed Evolution

Instigators of Change 

Angela Belcher spoke with the Instigators of Change podcast about how her career has evolved from working on batteries and solar cells to developing new tools for cancer diagnostics and environmental remediation. Highlights include the story of how the Koch Institute's early-years boot camps and speed dating sessions helped spark her passion for fighting ovarian cancer, and her top tips for team-building and getting inventions to market.
 

Immuno-Pep Squad

Nature

The immune system’s ability to detect nascent tumors requires the presentation of protein fragment (peptide) antigens that it can recognize. Due to limitations in how samples are collected and studied, researchers have difficulty identifying peptide presentation patterns specific to cancer. However, an ongoing Jacks Lab/White Lab collaboration, originally begun as a hallway conversation between colleagues, shows the power of combining engineered mouse models with mass spectrometry to better profile the collection of immunopeptides on the surface of cancer cells. The researchers' latest paper, published in Nature, reveals new tumor antigens potentially useful for immunotherapies and understanding of immune response.

Phenotype Phenomenon

MIT News

The Weissman Lab has produced the first map tying every human gene to its function in a cell. In a study published in Cell, researchers used the map to explore the effect of genes with previously unknown functions, investigate the response of mitochondria to stress, and screen for genes that cause chromosomes to be lost or gained.  

Model Behavior

MIT News

Glioblastoma, an aggressive form of brain cancer, is notoriously hard to treat. The blood-brain barrier blocks conventional chemotherapies from reaching tumors, and many potential new treatments that work well in animal models end up failing in clinical trials.

In a study published in PNAS and co-led by Charles W. (1955) and Jennifer C. Johnson Clinical Investigator Joelle Straehla, researchers assessed tumor-targeting nanoparticles from the Hammond Lab using a microfluidic human tissue model of glioblastoma from the Kamm Lab that closely replicates the blood-brain barrier. They found that cisplatin-bearing nanoparticles coated with peptide AP2 were able to target and kill glioblastoma tumor cells, suggesting that the model could be used to design nanoparticles with a greater chance of success in the clinic.

Signal Boost

MIT News

The Strano Lab developed a photonic technique that dramatically improves the signal of fluorescent sensors, potentially enabling their use for cancer diagnosis or monitoring. In a Nature Nanotechnology study funded in part by the Bridge Project, researchers were able to implant sensors as deep as 5.5 cm and still get a strong signal.

Pinpointing Solutions for Cancer Detection

MIT Spectrum

Ovarian cancer is notoriously hard to detect. Lacking in reliable diagnostic or screening techniques and opaque in its biological origins, it is difficult to find or target until it has progressed to dangerously late stages. The Hammond and Irvine Labs, in conjunction with their clinical collaborators and a cohort of patients, are determined to change this.

Drawing on years of expertise in engineering, immunology, and materials chemistry, and on recent funding from the Bridge Project, a multi-disciplinary team of researchers has built a polymer microneedle patch that samples interstitial fluid in the body to screen for microRNAs from cancer cells. The patch, which also has applications for autoimmune diseases, could one day become the first noninvasive screening tool for ovarian cancer.

Ultimate Frisbee

Nature Materials

Substantial delivery challenges persist for agents that engage the STING pathway, a highly desirable cancer immunotherapy target. However, new tumor-penetrating lipid nanodiscs developed by the Irvine Lab outperformed previously designed nanoparticles in delivering STING-activating agents to induce tumor rejection and support immune memory against reintroduced tumor cells. This work was published in Nature Materials and supported in part by the Marble Center for Cancer Nanomedicine.

Studying Cancer Across Continents

MIT News

New MIT alum and aspiring MD/PhD student Daniel Zhang is headed to the Netherlands on a Fulbright scholarship. His planned project, developing an organoid co-culture system to study malignant rhabdoid tumors and screen for therapeutic vulnerabilities, builds on his longtime work in the Jacks Lab developing genetic knockout models for colorectal cancer.

Becoming Bob Langer

Becoming X

A new installment of the Bear Grylls Becoming X series features Bob Langer, who shares how he ended up in the chemical engineering field, how he eventually achieved his research goals, and how he’s put them to work in service of millions of people worldwide.
 

With an AI Towards the Clinic

MIT News

Regina Barzilay co-chaired the AI Cures conference for physicians and researchers interested in bringing artificial intelligence tools into the clinic. Fellow KI members Susan Hockfield and Phillip Sharp and Bridge Project collaborator Lecia Sequest were among those who attended the event, which was co-hosted by MIT and Mass General Brigham.